- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05761795
Effekten av IVMED-85 på pediatrisk nærsynthet
A Randomized, Vehicle-Controlled, Double-Masked Study of the Efficacy and Safety of IVMED-85 Ophthalmic Solution for the Treatment of Pediatric Myopia
To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia.
The main aims are:
- Assess the efficacy of a 12-month treatment of IVMED-85 in slowing myopia progression in pediatrics
- Assess the safety of a 12-month treatment of IVMED-85
Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This is a multicenter, randomized, vehicle-controlled, double-masked study conducted in the United States (US) in subjects with pediatric myopia in both eyes.
Approximately 144 subjects will be stratified by age group (5 to 7 years of age; 8 to 10 years of age) and randomized (1:1:1) to one of three investigational products (IPs): IVMED-85 ophthalmic solution low-dose or high-dose; or vehicle ophthalmic solution. The study will use stratified block randomization by age group, with a 1:1:1 allocation within each stratum.
Subjects will administer their assigned IP in both eyes two times a day (BID) for approximately 12 months before entering a non-interventional period of approximately 4 months. Subjects will administer their IP under the supervision of a parent/guardian. Subjects who cannot independently apply IP can have their parent/guardian administer IP for them.
The study eye (SE) will be the more myopic eye. If both eyes are equally myopic in spherical equivalent, the eye with more spherical myopia (and less astigmatism) will be chosen as the study eye. If both eyes are equally myopic and astigmatic, the right eye (OD) will be the study eye.
A Data and Safety Monitoring Committee (DSMC) will be convened and will provide ongoing review of cumulative safety data throughout study conduct, inclusive of a Month 4 interim analysis of unmasked safety data.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Sarah Molokhia, RPH, PhD
- Telefonnummer: 385-229-4491
- E-post: smolokhia@iveenamed.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Subjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.
- Are 5 to 10 years of age
- Have a minimum body weight of 15.45 kg (34 lbs)
- Willing and able to provide informed consent and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
- Willing and able to comply with clinic visits and study-related procedures
- Able to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
- Willing and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
- Have refractive error as determined by cycloplegic autorefraction: myopia -0.50 D to -7.0 D (spherical equivalent); astigmatism ≤3.00 D; anisometropia ≤2.00 D
- Have BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
- Have corneal thickness between 450 and 680 μm
- Have IOP ≤22 mmHg
- Have axial length ≥20 mm and ≤27 mm
- Willing to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
- Willing to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: IVMED-85 Low Dose
Total subjects n=48, IVMED-85 low dose BID for 12 months |
Eye drop |
|
Eksperimentell: IVMED-85 High Dose
Total subjects n=48, IVMED-85 high dose BID for 12 months |
Eye drop |
|
Placebo komparator: Placebo
Total subjects n=48, placebo BID for 12 months |
Eye drop |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Refractive error change from baseline at Month 12
Tidsramme: Baseline compared to month 12
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction) in the SE at Month 12 |
Baseline compared to month 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
Tidsramme: From screening to the end of treatment at 12 months
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic manifest refraction) in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
|
Change in optical biometrics
Tidsramme: From screening to the end of treatment at 12 months
|
Change from baseline in keratometry, axial length, and vitreous chamber depth in the SE at all post-baseline visits |
From screening to the end of treatment at 12 months
|
|
Refractive error at non-final study visits
Tidsramme: From screening to the end of treatment at 12 months
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction and cycloplegic manifest refraction) in the SE at all post-baseline visits other than Month 12 |
From screening to the end of treatment at 12 months
|
|
Sub foveal choroidal thickness
Tidsramme: From screening to the end of treatment at 12 months
|
Change from baseline in sub foveal choroidal thickness in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
|
Accommodative amplitude in the spherical equivalent
Tidsramme: From screening to the end of treatment at 12 months
|
Change from baseline in accommodative amplitude in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression of high myopia
Tidsramme: From screening to the end of treatment at 12 months
|
Proportion of subjects with baseline myopia of -5 to -5.75 D progressing to -6.25 or worse at Month 12 |
From screening to the end of treatment at 12 months
|
|
Progression of prospectively identified progressive myopia
Tidsramme: From screening to the end of treatment at 12 months
|
Myopia progression at Month 12 in subjects prospectively identified at baseline as having progressive myopia, defined as an increase of 0.50 D or more in cycloplegic refractive myopia in the previous year based on historical chart records |
From screening to the end of treatment at 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Bala Ambati, iVeena Delivery Systems, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IVNA 26-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .